Learn how the biomarker test helps you get the best treatment!
Cancer is the name given to a group of diseases characterized by the abnormal proliferation of cells that can invade different tissues of the body. While healthy cells grow and divide in a controlled manner, cancer cells multiply out of control.
Tumours begin to develop when a cell acquires a series of mutations that allow it to divide uncontrollably.
Multiplication of abnormal cells causes the volume of the tissue to increase, a phenomenon called hyperplasia. Further mutations may occur, which further affect the control of cell growth.
In addition to showing uncontrolled proliferation, the cells are abnormally shaped. The tissue is now said to show dysplasia. After a while, new genetic changes may occur.
Mutated cells become even more abnormal in size and appearance, but for the moment they have not spread to other parts of the body. This is called carcinoma in situ, and it may remain confined indefinitely to the area from which it arose.
If genetic changes give the abnormal cells the potential for spreading to lymph nodes and nearby tissues, the cancer is said to be invasive. Cells are likely to give rise to new tumors (metastases) throughout the body.
Each cancer has a different combination of mutations in its DNA. This is what makes a tumour unique.
Biomarker testing help to establish, what we could call, the fingerprinting of a cancer.
There are several types of DNA mutations: single nucleotide variant (SNV), deletion or insertion of DNA nucleotides (indel), fusion of two DNA fragments to create an oncogene, and the amplification (copy/paste) of a same fragment of DNA (CNV). All these mutations can be detected by complex testing of biomarkers.
In addition to DNA mutations, a tumour may also show many surface proteins that could help identify the best therapy. OncoDNA is a pioneer in analysing not only the DNA of the tumour but also its proteins. Tumor proteins are visualized using a tumor cell staining technique called “immunohistochemistry.”
The past decades have seen significant progress in the understanding of cancer biology, and oncologists can now choose a treatment based on the presence of specific biomarkers. Biomarker testing and personalised treatment strategies can increase the chances of survival, as well as avoid unnecessary treatments and their adverse events.
ONCODEEP® IS A COMPREHENSIVE BIOMARKER TEST DESIGNED TO GUIDE TREATMENT OF ADVANCED, METASTATIC SOLID TUMORS.
When your patients are diagnosed with a rare cancer type or an aggressive cancer, when chemotherapy doesn’t work or when cancer comes back, OncoDEEP® can provide you with clear clinical guidance. Starting from a small sample of tumor tissue, our biomarker test is able to pinpoint the therapeutic vulnerabilities of a tumor and identify appropriate cancer treatment options in a fast turnaround.
OncoDEEP® is the most comprehensive biomarker test available on the market. It covers a wide range of cancer biomarkers carefully selected for their clinical relevance and offers a unique combination of analyses (NGS test and IHC test) that proved to maximize the clinical benefits for cancer patients.
In one simple biomarker test and in less than two weeks, OncoDEEP® can help you to:
THE LIQUID BIOPSY SOLUTION FOR DISEASE MONITORING OR THERAPEUTIC DECISION
OncoSELECT is a fast and minimally invasive analysis of circulating tumor DNA from a blood sample for lung (NSCLC), colorectal and breast (HR+ or HER2+) cancer patients.
It is the perfect solution to identify therapeutic options for cancer patients not able to have their tumor biopsied or whose biopsy is too old. It can be used as a tool to detect treatment resistance to targeted therapies (before first-line to check the heterogeneity of the disease, or during/after treatment to check for acquired resistance mutations), as well as for monitoring cancer progression.
The following stage IV solid tumors in adults:
2 blood samples (2x10ml Streck tubes)
OncoFOLLOW: The first personalised liquid biopsy in the market
MONITOR THE PROGRESSION AND DETECT LACK OF RESPONSE
OncoFOLLOW is a test based on the analysis of circulating tumor DNA in blood. It is used to monitor the progression of the tumor (burden of the disease) and to detect lack of response or resistance to treatment as soon as it appears.
This assay is customised for each patient, as it analyses up to 15 variants previously identified in the tumour of the patient. In addition, it sequences a fixed panel of 40 genes associated with response/resistance to targeted therapies and immunotherapy, and/or frequently mutated in cancer.
All stage IV solid tumours in adults that have been previously sequenced (with OncoDEED or any other test sequencing more than 100 genes).
2 blood samples (2x10ml Streck tubes)